Charles Sawyers - Publications

University of California, Los Angeles, Los Angeles, CA 
Molecular Biology, Immunology, Cell Biology, Animal Physiology Biology

181 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Mao N, Zhang Z, Lee YS, Choi D, Rivera AA, Li D, Lee C, Haywood S, Chen X, Chang Q, Xu G, Chen HA, de Stanchina E, Sawyers C, Rosen N, et al. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nature Communications. 12: 5053. PMID 34417459 DOI: 10.1038/s41467-021-25341-9  0.374
2021 Feng W, Cao Z, Lim PX, Zhao H, Luo H, Mao N, Lee YS, Rivera AA, Choi D, Wu C, Han T, Romero R, de Stanchina E, Carver BS, Wang Q, ... ... Sawyers CL, et al. Rapid interrogation of cancer cell of origin through CRISPR editing. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34353917 DOI: 10.1073/pnas.2110344118  0.777
2020 Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, Thoren KL, Abida W, Sfanos KS, De Marzo AM, Yegnasubramanian S, Fox JJ, Haas M, Heath H, Kagey MH, ... ... Sawyers CL, et al. Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. Jco Precision Oncology. 4. PMID 33015525 DOI: 10.1200/PO.20.00097  0.347
2020 Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, ... ... Sawyers CL, et al. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. PMID 32679108 DOI: 10.1016/J.Ccell.2020.06.005  0.702
2020 Leibold J, Ruscetti M, Cao Z, Ho YJ, Baslan T, Zou M, Abida W, Feucht J, Han T, Barriga FM, Tsanov KM, Zamechek L, Kulick A, Amor C, Tian S, ... ... Sawyers CL, et al. Somatic tissue engineering in mouse models reveals an actionable role for WNT pathway alterations in prostate cancer metastasis. Cancer Discovery. PMID 32376773 DOI: 10.1158/2159-8290.Cd-19-1242  0.342
2020 Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, ... ... Sawyers CL, et al. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell. PMID 32220301 DOI: 10.1016/J.Ccell.2020.03.001  0.662
2020 Quintanal-Villalonga Á, Chan JM, Yu HA, Pe'er D, Sawyers CL, Triparna S, Rudin CM. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nature Reviews. Clinical Oncology. PMID 32152485 DOI: 10.1038/s41571-020-0340-z  0.345
2020 Mao N, Gao D, Hu W, Gadal S, Hieronymus H, Wang S, Lee YS, Sullivan P, Zhang Z, Choi D, Rosen N, Sawyers CL, Gopalan A, Chen Y, Carver BS. Oncogenic ERG represses PI3K signaling through down-regulation of IRS2. Cancer Research. PMID 32015092 DOI: 10.1158/0008-5472.Can-19-1394  0.331
2019 Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, ... ... Sawyers CL, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31363002 DOI: 10.1158/1078-0432.Ccr-19-1423  0.351
2019 Zhu B, Cao A, Li J, Young J, Wong J, Ashraf S, Bierzynska A, Menon MC, Hou S, Sawyers C, Campbell KN, Saleem MA, He JC, Hildebrandt F, D'Agati VD, et al. Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2. Kidney International. PMID 31171376 DOI: 10.1016/J.Kint.2019.03.016  0.35
2019 Lee E, Wongvipat J, Choi D, Wang P, Lee YS, Zheng D, Watson PA, Gopalan A, Sawyers CL. amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance. Elife. 8. PMID 30644358 DOI: 10.7554/Elife.41913  0.349
2019 Kubler K, Karlic R, Haradhvala NJ, Ha K, Kim J, Kuzman M, Jiao W, Gakkhar S, Mouw KW, Braunstein LZ, Elemento O, Biankin AV, Rooman I, Miller M, Nogiec CD, ... ... Sawyers C, et al. Abstract 2727: The premalignant state captured in the landscape of somatic mutations can reveal the cancer cell-of-origin Cancer Research. 79: 2727-2727. DOI: 10.1158/1538-7445.Am2019-2727  0.393
2019 Zhang Z, Karthaus W, Mota JM, Mu P, Wu C, Abida W, Linton E, Lee YS, Lee E, Mao N, Adams E, Choi D, Rathkopf DE, Carver B, Gopalan A, ... ... Sawyers C, et al. Abstract 111: Tumor microenvironment derived NRG1 promotes antiandrogen resistance in prostate cancer Cancer Research. 79: 111-111. DOI: 10.1158/1538-7445.Am2019-111  0.729
2018 Karthaus WR, Sawyers CL. Strategies to Identify and Target Cells of Origin in Prostate Cancer. Journal of the National Cancer Institute. PMID 30312421 DOI: 10.1093/jnci/djy146  0.311
2018 Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, ... ... Sawyers CL, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications. 9: 2404. PMID 29921838 DOI: 10.1038/s41467-018-04495-z  0.335
2018 Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, ... ... Sawyers CL, et al. The long tail of oncogenic drivers in prostate cancer. Nature Genetics. PMID 29610475 DOI: 10.1038/S41588-018-0078-Z  0.34
2017 Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, ... ... Sawyers CL, et al. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology. PMID 29258679 DOI: 10.1016/J.Eururo.2017.11.038  0.301
2017 Hieronymus H, Iaquinta PJ, Wongvipat J, Gopalan A, Murali R, Mao N, Carver BS, Sawyers CL. Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. Nature Communications. 8: 1081. PMID 29057879 DOI: 10.1038/S41467-017-01198-9  0.346
2017 Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 6. PMID 28891793 DOI: 10.7554/Elife.27861  0.37
2017 Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, ... ... Sawyers CL, et al. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. Jco Precision Oncology. 2017. PMID 28825054  0.307
2017 Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y, ... ... Sawyers CL, et al. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature. PMID 28614298 DOI: 10.1038/Nature22820  0.353
2017 Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, ... ... Sawyers CL, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science (New York, N.Y.). 355: 84-88. PMID 28059768 DOI: 10.1126/Science.Aah4307  0.709
2017 Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers CL, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science (New York, N.Y.). 355: 78-83. PMID 28059767 DOI: 10.1126/Science.Aah4199  0.701
2016 Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, Zhang L, Huang K, Stoyanova T, Park JW, Shkhyan RO, Nowroozizadeh B, Rettig MB, Sawyers CL, Elashoff D, et al. Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Reports. 17: 2596-2606. PMID 27926864 DOI: 10.1016/J.Celrep.2016.11.010  0.661
2016 Gao D, Zhan Y, Di W, Moore AR, Sher JJ, Guan Y, Wang S, Zhang Z, Murphy DA, Sawyers CL, Chi P, Chen Y. A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. Plos One. 11: e0161084. PMID 27536883 DOI: 10.1371/Journal.Pone.0161084  0.31
2016 Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, ... ... Sawyers C, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England Journal of Medicine. PMID 27433846 DOI: 10.1056/Nejmoa1603144  0.4
2016 Drost J, Karthaus WR, Gao D, Driehuis E, Sawyers CL, Chen Y, Clevers H. Organoid culture systems for prostate epithelial and cancer tissue. Nature Protocols. 11: 347-58. PMID 26797458 DOI: 10.1038/Nprot.2016.006  0.653
2016 Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers CL, Lewis JS, Evans MJ. Applying 89Zr-transferrin to study the pharmacology of inhibitors to BET bromodomain containing proteins. Molecular Pharmaceutics. PMID 26725682 DOI: 10.1021/Acs.Molpharmaceut.5B00882  0.319
2016 Bose R, Abida W, Iaquinta P, Karthaus W, Armenia J, Wongvipat J, Doran M, Hieronymus H, Philip W, Liang Y, Schultz N, Sawyers CL. Investigation of a frequently mutated transcriptional repressor in prostate cancer, in particular its role in modulating androgen signaling and its effects on TMPRSS2-ERG dependent tumor maintenance. Journal of Clinical Oncology. 34: 274-274. DOI: 10.1200/Jco.2016.34.2_Suppl.274  0.344
2016 Wise D, Louw J, Krupa R, Schreiber NA, Sawyers CL, Dittamore RV, Scher HI. Detection of glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) from patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 34: 5046-5046. DOI: 10.1200/JCO.2016.34.15_SUPPL.5046  0.329
2016 Agarwal S, Hynes P, Lake R, Fang L, Tillman H, Beshiri M, Jansson K, Karthaus W, Iaquinta P, Sawyers C, Kelly K. Abstract LB-276: The identification and characterization of prostate adenocarcinoma tumor initiating cells Cancer Research. 72. DOI: 10.1158/1538-7445.Am2016-Lb-276  0.399
2016 Bose R, Abida W, Karthaus W, Armenia J, Iaquinta P, Wongvipat J, Doran M, Hieronymus H, Watson P, Sullivan P, Liang Y, Schultz N, Sawyers C. Abstract LB-018: Loss of function mutations of an ETS repressor expand the ETS positive subset of prostate cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-018  0.456
2016 Vis DJ, Lewin J, Siu L, Liao R, Zenklusen JC, Calvo F, Szepessy E, Vivancos A, Wirta V, Madhavan S, Park K, Tan D, Laskin J, Brammer M, Dias-Neto E, ... ... Sawyers C, et al. Abstract 5287: Heterogeneity of mutation calling and annotation: a survey of cancer next-generation sequencing initiatives by the Global Alliance for Genomics and Health (GA4GH): Cancer Research. 76: 5287-5287. DOI: 10.1158/1538-7445.Am2016-5287  0.306
2016 Shah N, Arora V, Karthaus W, Wongvipat J, Zheng D, Sawyers C. A distinct epigenetic state sensitizes enzalutamide-resistant prostate cancer cells to BET bromodomain inhibition European Journal of Cancer. 61: S9. DOI: 10.1016/S0959-8049(16)61020-1  0.331
2015 Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nature Reviews. Cancer. PMID 26563462 DOI: 10.1038/nrc4016  0.343
2015 Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL. Androgen receptor upregulation mediates radioresistance after ionizing radiation. Cancer Research. PMID 26432404 DOI: 10.1158/0008-5472.Can-15-0892  0.329
2015 Wheeler DB, Zoncu R, Root DE, Sabatini DM, Sawyers CL. Identification of an oncogenic RAB protein. Science (New York, N.Y.). 350: 211-7. PMID 26338797 DOI: 10.1126/Science.Aaa4903  0.346
2015 Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, ... ... Sawyers CL, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 161: 1215-28. PMID 26000489 DOI: 10.1016/J.Cell.2015.05.001  0.662
2015 Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N. Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell. 27: 109-22. PMID 25544636 DOI: 10.1016/j.ccell.2014.11.008  0.334
2015 Wanjala J, Taylor BS, Chapinski C, Hieronymus H, Wongvipat J, Chen Y, Nanjangud GJ, Schultz N, Xie Y, Liu S, Lu W, Yang Q, Sander C, Chen Z, Sawyers CL, et al. Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. Molecular Cancer Therapeutics. 14: 278-88. PMID 25381262 DOI: 10.1158/1535-7163.Mct-14-0542-T  0.688
2015 Mu P, Cao Z, Hoover E, Wongvipat J, Huang C, Karthaus W, Abida W, Stanchina ED, Sawyers C. Abstract LB-056: TP53 and RB1 alterations promote reprogramming and antiandrogen resistance in advanced prostate cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-056  0.735
2014 Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, ... ... Sawyers CL, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 159: 176-87. PMID 25201530 DOI: 10.1016/J.Cell.2014.08.016  0.682
2014 Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, Vries RG, Cuppen E, Chen Y, Sawyers CL, Clevers HC. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell. 159: 163-75. PMID 25201529 DOI: 10.1016/j.cell.2014.08.017  0.642
2014 Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia (New York, N.Y.). 16: 14-20. PMID 24563616 DOI: 10.1593/Neo.131704  0.422
2014 Vela I, Gao D, Gopalan A, Sboner A, Undvall E, Wanjala J, Iaquinta P, Wongvipat J, Karthaus W, Clevers H, Solomon SB, Beltran H, Kossai M, Mosquera JM, Rubin MA, ... ... Sawyers CL, et al. Development of novel metastatic prostate cancer cell lines by “organoid” in vitro culture technology. Journal of Clinical Oncology. 32: 33-33. DOI: 10.1200/Jco.2014.32.4_Suppl.33  0.302
2014 Rathkopf DE, Carver BS, Chen Y, Morris MJ, Danila DC, Slovin SF, Autio KA, DeNunzio M, Sawyers CL, Scher HI. Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 32: TPS5106-TPS5106. DOI: 10.1200/JCO.2014.32.15_SUPPL.TPS5106  0.362
2014 Vela I, Gao D, Gopalan A, Sboner A, Undvall E, Wanjala J, Iaquinta P, Wongvipat J, Dowling C, Karthaus W, Clevers H, Solomon SB, Beltran H, Kossai M, Mosquera JM, ... ... Sawyers C, et al. MP31-01 DEVELOPMENT OF NOVEL METASTATIC PROSTATE CANCER CELL LINES BY “ORGANOID” IN VITRO CULTURE TECHNOLOGY Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.910  0.387
2014 Blattner M, Lee D, O'Reilly C, Park K, MacDonald T, Khani F, Turner K, Chiu Y, Wild P, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari A, Andren O, et al. MP41-06 SPOP MUTATIONS IN PROSTATE CANCER ACROSS DEMOGRAPHICALLY DIVERSE PATIENT COHORTS. Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1223  0.445
2013 Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 155: 1309-22. PMID 24315100 DOI: 10.1016/J.Cell.2013.11.012  0.331
2013 Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D, Carver BS, Chen Y, Watson PA, Shah NP, Fujisawa S, ... ... Sawyers CL, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discovery. 3: 1245-53. PMID 24027196 DOI: 10.1158/2159-8290.Cd-13-0172  0.639
2013 Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, Larson SM, Sawyers CL, Scher HI. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3525-30. PMID 24002508 DOI: 10.1200/JCO.2013.50.1684  0.307
2013 Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J, Scher HI, Zheng D, Sawyers CL. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine. 19: 1023-9. PMID 23817021 DOI: 10.1038/Nm.3216  0.661
2013 Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2: e00499. PMID 23580326 DOI: 10.7554/Elife.00499  0.671
2013 Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL, Giancotti FG. β4 Integrin signaling induces expansion of prostate tumor progenitors. The Journal of Clinical Investigation. 123: 682-99. PMID 23348745 DOI: 10.1172/Jci60720  0.689
2012 Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. Annotating MYC status with 89Zr-transferrin imaging. Nature Medicine. 18: 1586-91. PMID 23001181 DOI: 10.1038/Nm.2935  0.307
2012 Hübner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T, Chi H, Greiner DL, Tournier C, Sawyers CL, Flavell RA, Wu H, Davis RJ. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proceedings of the National Academy of Sciences of the United States of America. 109: 12046-51. PMID 22753496 DOI: 10.1073/Pnas.1209660109  0.358
2012 Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, ... ... Sawyers C, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genetics. 44: 852-60. PMID 22751098 DOI: 10.1038/Ng.2330  0.438
2012 Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discovery. 2: 320-7. PMID 22576209 DOI: 10.1158/2159-8290.Cd-11-0316  0.305
2012 Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL. Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening Plos One. 7. PMID 22509301 DOI: 10.1371/Journal.Pone.0034414  0.353
2012 Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, ... ... Sawyers CL, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research. 72: 1494-503. PMID 22266222 DOI: 10.1158/0008-5472.Can-11-3948  0.673
2012 Iaquinta PJ, Wai Chua C, Machado-Pinilla R, Hieronymus H, Wongvipat J, Meier UT, Shen M, Sawyers CL. Abstract PR3: The snoRNP assembly factor SHQ1 is a novel prostate cancer tumor suppressor gene Cancer Research. 72: PR3-PR3. DOI: 10.1158/1538-7445.Prca2012-Pr3  0.368
2012 Chen Y, Shukla S, Chi P, Carver B, Sawyers CL. Abstract IA15: Context-specific oncogenesis by ETS-family transcription factors Cancer Research. 72: IA15-IA15. DOI: 10.1158/1538-7445.Prca2012-Ia15  0.301
2012 Sawyers CL. Abstract IA10: Overcoming castration-resistant prostate cancer Cancer Research. 72: IA10-IA10. DOI: 10.1158/1538-7445.PRCA2012-IA10  0.311
2012 Joseph JD, Aparicio A, Kaufman J, Julien J, Bonnefous C, Smith ND, Rix P, Jung ME, Sawyers CL, Heyman RA, Hager JH, Clegg NJ, Sensintaffar J, Lu N, Grillot K, et al. Abstract C16: Targeting AR in castration-resistant prostate cancer: Development of ARN-509 and second-generation antiandrogen resistance models Cancer Research. 72: C16-C16. DOI: 10.1158/1538-7445.PRCA2012-C16  0.305
2011 Rathkopf DE, Danila DC, Slovin SF, Morris MJ, Steinbrecher JE, Chen Y, Fleisher M, Larson SM, Sawyers CL, Scher HI. A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS190. PMID 28023073 DOI: 10.1200/jco.2011.29.15_suppl.tps190  0.325
2011 Leder K, Foo J, Skaggs B, Gorre M, Sawyers CL, Michor F. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. Plos One. 6: e27682. PMID 22140458 DOI: 10.1371/Journal.Pone.0027682  0.763
2011 Paquette RL, Nicoll J, Chalukya M, Elashoff D, Shah NP, Sawyers C, Spiteri E, Nanjangud G, Rao PN. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genetics. 204: 392-7. PMID 21872826 DOI: 10.1016/J.Cancergen.2011.06.002  0.439
2011 Chen Y, Shamu T, Chen H, Besmer P, Sawyers CL, Chi P. Visualization of the interstitial cells of cajal (ICC) network in mice. Journal of Visualized Experiments : Jove. PMID 21841758 DOI: 10.3791/2802  0.598
2011 Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. European Urology. 60: 897-904. PMID 21802835 DOI: 10.1016/j.eururo.2011.07.011  0.343
2011 Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, ... ... Sawyers CL, et al. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Science Translational Medicine. 3: 85ra47. PMID 21632985 DOI: 10.1126/scitranslmed.3002004  0.312
2011 Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences of the United States of America. 108: 9578-82. PMID 21606347 DOI: 10.1073/pnas.1106383108  0.325
2011 Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 19: 575-86. PMID 21575859 DOI: 10.1016/J.Ccr.2011.04.008  0.698
2011 Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, Ellwood-Yen K, Gerald WL, Sander C, Sawyers CL. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. Plos One. 6: e17449. PMID 21394210 DOI: 10.1371/Journal.Pone.0017449  0.365
2011 Zhang Y, Hsieh J, Maitra A, Rudin CM, Brekken RA, Sawyers C, Stastny V, Gao B, Frenkel E, Minna JD, Gazdar AF. Abstract 4292: Frequent detection of xenotropic murine leukemia virus (XMLV) strains including XMRV in human cultures established from mouse xenografts Cancer Research. 71: 4292-4292. DOI: 10.1158/1538-7445.Am2011-4292  0.307
2010 Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 467: 849-53. PMID 20927104 DOI: 10.1038/Nature09409  0.67
2010 Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America. 107: 16759-65. PMID 20823238 DOI: 10.1073/pnas.1012443107  0.681
2010 Chen Y, Sawyers CL. Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. Cancer Cell. 17: 415-6. PMID 20478521 DOI: 10.1016/j.ccr.2010.04.022  0.646
2010 Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, ... ... Sawyers CL, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 375: 1437-46. PMID 20398925 DOI: 10.1016/S0140-6736(10)60172-9  0.303
2010 Jung ME, Ouk S, Yoo D, Sawyers CL, Chen C, Tran C, Wongvipat J. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). Journal of Medicinal Chemistry. 53: 2779-96. PMID 20218717 DOI: 10.1021/Jm901488G  0.303
2010 Nandana S, Ellwood-Yen K, Sawyers C, Wills M, Weidow B, Case T, Vasioukhin V, Matusik R. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model. The Prostate. 70: 591-600. PMID 19938013 DOI: 10.1002/Pros.21093  0.427
2009 Mitsiades N, Schultz N, Taylor BS, Hieronymus H, Satagopan J, Scardino PT, Reuter VE, Sander C, Sawyers C, Scher HI. Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5002. PMID 27962896 DOI: 10.1200/Jco.2009.27.15_Suppl.5002  0.433
2009 King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature Genetics. 41: 524-6. PMID 19396167 DOI: 10.1038/Ng.371  0.37
2009 Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, ... ... Sawyers CL, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (New York, N.Y.). 324: 787-90. PMID 19359544 DOI: 10.1126/Science.1168175  0.672
2009 Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Research. 69: 958-66. PMID 19176386 DOI: 10.1158/0008-5472.CAN-08-2216  0.681
2009 Parsons JK, Saria EA, Nakayama M, Vessella RL, Sawyers CL, Isaacs WB, Faith DA, Bova GS, Samathanam CA, Mitchell R, De Marzo AM. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. The Prostate. 69: 559-69. PMID 19142959 DOI: 10.1002/Pros.20904  0.337
2009 Scher HI, Danila DC, Beer TM, Higano C, Rathkopf D, Taplin M, Efstathiou E, Anand A, Hung D, Hirmand M, Seely L, Larson SM, Fleisher M, Sawyers C. Abstract CN02-03: Circulating tumor cells as biomarkers in the development of the androgen receptor antagonist, MDV3100 Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-Cn02-03  0.317
2009 Scher HI, Beer T, Higano C, Efstathiou E, Anand A, Hirmand M, Hung D, Steve L, Fleisher M, Sawyers C. CLINICAL STUDY OF MDV3100 IN PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER (CRPC) Journal of Urology. 181: 230-230. DOI: 10.1016/S0022-5347(09)60655-8  0.431
2008 Scher HI, Beer TM, Higano CS, Danila DC, Montgomery B, Shelkey J, Hirmand M, Hung D, Sawyers C. Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5006. PMID 27948609 DOI: 10.1200/Jco.2008.26.15_Suppl.5006  0.403
2008 Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 14: 485-93. PMID 19061839 DOI: 10.1016/J.Ccr.2008.11.001  0.318
2008 Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Research. 68: 6762-9. PMID 18701501 DOI: 10.1158/0008-5472.Can-08-0107  0.338
2008 Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, ... Sawyers CL, et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 14: 146-55. PMID 18691549 DOI: 10.1016/J.Ccr.2008.06.002  0.34
2008 Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Current Opinion in Pharmacology. 8: 440-8. PMID 18674639 DOI: 10.1016/j.coph.2008.07.005  0.693
2008 Duncan EA, Goetz CA, Stein SJ, Mayo KJ, Skaggs BJ, Ziegelbauer K, Sawyers CL, Baldwin AS. IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Molecular Cancer Therapeutics. 7: 391-7. PMID 18245668 DOI: 10.1158/1535-7163.Mct-07-0305  0.331
2008 Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, ... ... Sawyers CL, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. Plos Medicine. 5: e8. PMID 18215105 DOI: 10.1371/Journal.Pmed.0050008  0.654
2008 Paquette R, Nicoll J, Chalukya M, Gondek LP, Jasek M, Sawyers C, Shah N, Maciejewski J. Clonal Hematopoiesis in Philadelphia Chromosome-Negative Bone Marrow Cells of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors Blood. 112: 575-575. DOI: 10.1182/Blood.V112.11.575.575  0.33
2007 Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency Journal of Clinical Investigation. 117: 2562-2569. PMID 17710227 DOI: 10.1172/Jci30890  0.354
2007 Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Research. 67: 6083-91. PMID 17616663 DOI: 10.1158/0008-5472.Can-06-4202  0.751
2007 Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell. 11: 555-69. PMID 17560336 DOI: 10.1016/J.Ccr.2007.04.021  0.757
2007 Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 104: 5563-8. PMID 17372210 DOI: 10.1073/pnas.0609139104  0.375
2006 Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, ... ... Sawyers CL, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. Plos Medicine. 3: e485. PMID 17177598 DOI: 10.1371/Journal.Pmed.0030485  0.743
2006 Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers CL, Graeber TG. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proceedings of the National Academy of Sciences of the United States of America. 103: 19466-71. PMID 17164333 DOI: 10.1073/Pnas.0609239103  0.772
2006 Ellwood-Yen K, Wongvipat J, Sawyers C. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Research. 66: 10513-6. PMID 17079473 DOI: 10.1158/0008-5472.Can-06-1397  0.395
2006 Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research. 66: 7864-9. PMID 16912159 DOI: 10.1158/0008-5472.Can-04-4392  0.755
2006 Burgess MR, Sawyers CL. Treating imatinib-resistant leukemia: the next generation targeted therapies. Thescientificworldjournal. 6: 918-30. PMID 16906325 DOI: 10.1100/tsw.2006.184  0.372
2006 Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 103: 2794-9. PMID 16477019 DOI: 10.1073/Pnas.0510423103  0.307
2006 Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Research. 66: 1007-14. PMID 16424036 DOI: 10.1158/0008-5472.Can-05-2788  0.329
2006 Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 107: 2501-6. PMID 16291594 DOI: 10.1182/Blood-2005-07-2966  0.767
2006 Cortes JE, Kim DW, Rosti G, Rousselot P, Bleickardt E, Zink R, Sawyers C. Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 ‘START-B’ study Journal of Clinical Oncology. 24: 6529-6529. DOI: 10.1200/Jco.2006.24.18_Suppl.6529  0.353
2006 Shah NP, Skaggs B, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential Kinase Inhibitor Therapy in CML Patients Can Select for Cells Harboring Compound BCR-ABL Kinase Domain Mutations with Increased Oncogenic Potency: Rationale for Early Combination Therapy of ABL Kinase Inhibitors. Blood. 108: 751-751. DOI: 10.1182/Blood.V108.11.751.751  0.337
2006 Shah NP, Skaggs B, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. The Most Common Dasatinib-Resistant BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Are Sensitive to VX-680: Rationale for Early Combination Kinase Inhibitor Therapy. Blood. 108: 2175-2175. DOI: 10.1182/Blood.V108.11.2175.2175  0.375
2006 Shah NP, Nicoll JM, Bleickardt E, Nicaise C, Paquette RL, Sawyers CL. Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development. Blood. 108: 2166-2166. DOI: 10.1182/Blood.V108.11.2166.2166  0.34
2005 Shah N, Sawyers CL, Kantarjian HM, Donato N, Nicoll J, Cortes J, Paquette R, Huang F, Clark E, Talpaz M. Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6521. PMID 27943866 DOI: 10.1200/Jco.2005.23.16_Suppl.6521  0.342
2005 Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Research. 65: 11565-71. PMID 16357166 DOI: 10.1158/0008-5472.CAN-05-3441  0.33
2005 Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, ... ... Sawyers CL, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. 353: 2012-24. PMID 16282176 DOI: 10.1056/Nejmoa051918  0.74
2005 Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8253-61. PMID 16278481 DOI: 10.1200/JCO.2005.03.4777  0.321
2005 Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, et al. Amplification and overexpression of prosaposin in prostate cancer. Genes, Chromosomes & Cancer. 44: 351-64. PMID 16080200 DOI: 10.1002/Gcc.20249  0.325
2005 Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, ... ... Sawyers CL, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proceedings of the National Academy of Sciences of the United States of America. 102: 11011-6. PMID 16046538 DOI: 10.1073/Pnas.0504952102  0.365
2005 Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature. 435: 1267-70. PMID 15988530 DOI: 10.1038/Nature03669  0.341
2005 Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proceedings of the National Academy of Sciences of the United States of America. 102: 3395-400. PMID 15705718 DOI: 10.1073/Pnas.0409770102  0.353
2005 Skaggs BJ, Burgess MR, Gorre ME, Graeber TG, Sawyers CL. Altered Oncogenic Fitness of Imatinib- and Dasatinib-Resistant BCR-ABL Mutants Is Due to Differential Intrinsic Kinase Activity and Signaling Pathway Selection Defined by Phosphoproteome Profiling. Blood. 106: 692-692. DOI: 10.1182/Blood.V106.11.692.692  0.771
2005 Branford S, Hughes T, Nicoll J, Paquette R, Bleickardt E, Sawyers C, Shah N. Major Molecular Responses to Dasatinib (BMS-354825) Are Observed in Imatinib-Resistant Late Stage Chronic and Advanced CML Patients: Impact and Fate of Imatinib-Resistant Clones in Dasatinib-Treated Patients. Blood. 106: 437-437. DOI: 10.1182/Blood.V106.11.437.437  0.365
2005 Oehler V, Branford S, Pogosova-Agadjanyan E, Shah N, Sawyers C, Mao M, Linsley P, Hughes T, Radich J. Gene Expression Signatures Associated with Treatment and Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients. Blood. 106: 433-433. DOI: 10.1182/Blood.V106.11.433.433  0.39
2005 Shah NP, Nicoll JM, Branford S, Hughes TP, Paquette RL, Talpaz M, Nicaise C, Huang F, Sawyers CL. Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy. Blood. 106: 1093-1093. DOI: 10.1182/Blood.V106.11.1093.1093  0.306
2005 SHAH N, NICOLL J, SAWYERS C. Targeted therapy for the treatment of imatinib-resistant chronic myeloid leukemia: A pharmacogenetic analysis Clinical Pharmacology & Therapeutics. 77: P17-P17. DOI: 10.1016/J.Clpt.2004.11.066  0.475
2004 Thomas GV, Horvath S, Smith BL, Crosby K, Lebel LA, Schrage M, Said J, De Kernion J, Reiter RE, Sawyers CL. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 8351-6. PMID 15623612 DOI: 10.1158/1078-0432.Ccr-04-0130  0.403
2004 Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 6: 517-27. PMID 15542435 DOI: 10.1016/J.Ccr.2004.09.031  0.764
2004 Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (New York, N.Y.). 305: 399-401. PMID 15256671 DOI: 10.1126/Science.1099480  0.381
2004 Shah NP, Lee FY, Sawyers CL, Akin C. BMS-354825 Is a SRC/ABL Inhibitor with High Nanomolar Activity Against the Kit D816v Mutation, Which Drives Systemic Mastocytosis and Is Imatinib-Resistant. Blood. 104: 797-797. DOI: 10.1182/Blood.V104.11.797.797  0.314
2004 Gorre ME, Skaggs BJ, Sawyers CL. Imatinib-Resistant BCR-ABL Mutations Alter Oncogenic Potency, Kinase Activity and Substrate Selection. Blood. 104: 556-556. DOI: 10.1182/Blood.V104.11.556.556  0.764
2004 Chandra J, Tracy J, Gorre M, Talpaz M, Griffin J, Verstovsek S, Beran M, Sawyers C, Sausville E, Kaufmann S. Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance. Blood. 104: 2097-2097. DOI: 10.1182/Blood.V104.11.2097.2097  0.77
2004 Parsons JK, Mitchell RJ, Vessella RL, Sawyers CL, Isaacs WB, Faith DA, Bova GS, De Marzo AM. 415: Mutational Analysis of the P63 Gene in Prostate Cancer Cells Journal of Urology. 171: 110-110. DOI: 10.1016/S0022-5347(18)37677-8  0.309
2003 Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias Oncogene. 22: 7389-7395. PMID 14576846 DOI: 10.1038/Sj.Onc.1206942  0.331
2003 Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 4: 223-38. PMID 14522256 DOI: 10.1016/S1535-6108(03)00197-1  0.321
2003 Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Research. 63: 2742-6. PMID 12782577  0.347
2003 Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1267-73. PMID 12684394  0.742
2002 Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 100: 3041-4. PMID 12351420 DOI: 10.1182/Blood-2002-05-1361  0.754
2002 Mellinghoff IK, Tran C, Sawyers CL. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts Cancer Research. 62: 5254-5259. PMID 12234993  0.407
2002 Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2: 117-25. PMID 12204532 DOI: 10.1016/S1535-6108(02)00096-X  0.753
2002 Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proceedings of the National Academy of Sciences of the United States of America. 99: 10700-5. PMID 12149456 DOI: 10.1073/Pnas.162140299  0.768
2002 Thomas M, Laura R, Hepner K, Guccione E, Sawyers C, Lasky L, Banks L. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene. 21: 5088-96. PMID 12140759 DOI: 10.1038/Sj.Onc.1205668  0.732
2002 Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell. 1: 413-5. PMID 12124170 DOI: 10.1016/S1535-6108(02)00080-6  0.317
2002 Gery S, Sawyers CL, Agus DB, Said JW, Koeffler HP. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene. 21: 4739-46. PMID 12101412 DOI: 10.1038/Sj.Onc.1205142  0.33
2002 Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews. Cancer. 2: 489-501. PMID 12094235 DOI: 10.1038/Nrc839  0.748
2002 Sawyers CL. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell. 1: 13-5. PMID 12086882 DOI: 10.1016/S1535-6108(02)00022-3  0.352
2002 Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Current Opinion in Hematology. 9: 303-7. PMID 12042704 DOI: 10.1097/00062752-200207000-00007  0.725
2002 Chen CD, Sawyers CL. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Molecular and Cellular Biology. 22: 2862-70. PMID 11909978 DOI: 10.1128/MCB.22.8.2862-2870.2002  0.341
2002 Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. The New England Journal of Medicine. 346: 645-52. PMID 11870241 DOI: 10.1056/Nejmoa011573  0.337
2002 Sawyers CL. Rational therapeutic intervention in cancer: kinases as drug targets. Current Opinion in Genetics & Development. 12: 111-5. PMID 11790564 DOI: 10.1016/S0959-437X(01)00273-8  0.334
2002 Sawyers CL. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Seminars in Hematology. 38: 15-21. PMID 11526597 DOI: 10.1016/S0037-1963(01)90113-1  0.341
2001 Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proceedings of the National Academy of Sciences of the United States of America. 98: 10314-9. PMID 11504908 DOI: 10.1073/Pnas.171076798  0.819
2001 Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, ... Sawyers C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proceedings of the National Academy of Sciences of the United States of America. 98: 10320-5. PMID 11504907 DOI: 10.1073/Pnas.171060098  0.803
2001 Tsukasaki K, Miller CW, Greenspun E, Eshaghian S, Kawabata H, Fujimoto T, Tomonaga M, Sawyers C, Said JW, Koeffler HP. Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene. 20: 3301-5. PMID 11423979 DOI: 10.1038/Sj.Onc.1204421  0.433
2001 Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (New York, N.Y.). 293: 876-80. PMID 11423618 DOI: 10.1126/Science.1062538  0.763
2000 Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, Wood J, Ross C, Sawyers CL, Whang YE. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proceedings of the National Academy of Sciences of the United States of America. 97: 4233-8. PMID 10760291 DOI: 10.1073/Pnas.97.8.4233  0.761
2000 Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Molecular and Cellular Biology. 20: 1179-86. PMID 10648603 DOI: 10.1128/Mcb.20.4.1179-1186.2000  0.798
2000 Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, Sawyers CL. Bcr-abl kinase inhibition as the basis of therapy for cml Experimental Hematology. 28: 130. DOI: 10.1016/S0301-472X(00)00503-8  0.312
1999 Huang W, Shostak Y, Tarr P, Sawyers C, Carey M. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. The Journal of Biological Chemistry. 274: 25756-68. PMID 10464314 DOI: 10.1074/Jbc.274.36.25756  0.391
1999 Craft N, Sawyers CL. Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Reviews. 17: 421-7. PMID 10453286 DOI: 10.1023/A:1006141806801  0.679
1999 Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Molecular and Cellular Biology. 19: 5143-54. PMID 10373563 DOI: 10.1128/Mcb.19.7.5143  0.711
1999 Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine. 5: 280-5. PMID 10086382 DOI: 10.1038/6495  0.706
1999 Reiter RE, Yamashiro J, Sawyers C, Loda M, Witte ON. A Type Ii Transmembrane Glycoprotein Associated With Osteogenesis Can Accelerate Androgen-Independent Prostate Cancer Progression In Vivo The Journal of Urology. 128. DOI: 10.1097/00005392-199904010-00516  0.566
1998 Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proceedings of the National Academy of Sciences of the United States of America. 95: 15587-91. PMID 9861013 DOI: 10.1073/Pnas.95.26.15587  0.826
1998 Senechal K, Heaney C, Druker B, Sawyers CL. Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. Molecular and Cellular Biology. 18: 5082-90. PMID 9710592 DOI: 10.1128/Mcb.18.9.5082  0.326
1998 Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proceedings of the National Academy of Sciences of the United States of America. 95: 5246-50. PMID 9560261 DOI: 10.1073/Pnas.95.9.5246  0.358
1998 Xu F, Sharma S, Gardner A, Tu Y, Raitano A, Sawyers C, Lichtenstein A. Interleukin-6–Induced Inhibition of Multiple Myeloma Cell Apoptosis: Support for the Hypothesis That Protection Is Mediated Via Inhibition of the JNK/SAPK Pathway Blood. 92: 241-251. DOI: 10.1182/Blood.V92.1.241.413K28_241_251  0.326
1997 Sawyers CL. Signal transduction pathways involved in BCR-ABL transformation. Bailliere's Clinical Haematology. 10: 223-31. PMID 9376661 DOI: 10.1016/S0950-3536(97)80004-2  0.301
1997 Dickens M, Rogers JS, Cavanagh J, Raitano A, Xia Z, Halpern JR, Greenberg ME, Sawyers CL, Davis RJ. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science (New York, N.Y.). 277: 693-6. PMID 9235893 DOI: 10.1126/Science.277.5326.693  0.32
1997 Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Medicine. 3: 402-8. PMID 9095173 DOI: 10.1038/Nm0497-402  0.53
1997 Senechal K, Sawyers CL. Signal transduction-based strategies for the treatment of chronic myelogenous leukemia. Molecular Medicine Today. 2: 503-9. PMID 9015791 DOI: 10.1016/S1357-4310(97)81454-2  0.308
1996 Yuan ZM, Huang Y, Fan MM, Sawyers C, Kharbanda S, Kufe D. Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53. The Journal of Biological Chemistry. 271: 26457-60. PMID 8900110 DOI: 10.1074/Jbc.271.43.26457  0.345
1996 Yuan ZM, Huang Y, Whang Y, Sawyers C, Weichselbaum R, Kharbanda S, Kufe D. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature. 382: 272-4. PMID 8717045 DOI: 10.1038/382272A0  0.356
1995 Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proceedings of the National Academy of Sciences of the United States of America. 92: 11746-50. PMID 8524841 DOI: 10.1073/PNAS.92.25.11746  0.319
1995 Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene Journal of Experimental Medicine. 181: 307-313. PMID 7807010 DOI: 10.1084/Jem.181.1.307  0.422
1994 Sawyers CL, Denny CT. Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about. Cell. 77: 171-3. PMID 8168126 DOI: 10.1016/0092-8674(94)90307-7  0.32
1994 Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of Bcr-Abl point mutants with c-Myc Science. 264: 424-426. PMID 8153630 DOI: 10.1126/Science.8153630  0.509
1994 Orr SL, Hughes TP, Sawyers CL, Kato RM, Quan SG, Williams SP, Witte ON, Hood L. Isolation of unknown genes from human bone marrow by differential screening and single-pass cDNA sequence determination. Proceedings of the National Academy of Sciences of the United States of America. 91: 11869-73. PMID 7991548 DOI: 10.1073/Pnas.91.25.11869  0.402
1994 Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth Cell. 77: 121-131. PMID 7512450 DOI: 10.1016/0092-8674(94)90240-2  0.521
1992 Sawyers CL, Gishizky ML, Quan S, Golde DW, Witte ON. Propagation of human elastic myeloid leukemias in the SCID mouse Blood. 79: 2089-2098. PMID 1562735 DOI: 10.1182/Blood.V79.8.2089.Bloodjournal7982089  0.493
1992 Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes Cell. 70: 901-910. PMID 1525828 DOI: 10.1016/0092-8674(92)90241-4  0.451
1991 Sawyers CL, Denny CT, Witte ON. Leukemia and the disruption of normal hematopoiesis Cell. 64: 337-350. PMID 1988151 DOI: 10.1016/0092-8674(91)90643-D  0.452
1990 Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witte ON, Champlin R. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proceedings of the National Academy of Sciences of the United States of America. 87: 563-7. PMID 2405384 DOI: 10.1073/Pnas.87.2.563  0.389
Show low-probability matches.